New updates have been reported about 4BIO Capital.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
4BIO Capital has strengthened its position in ophthalmology-focused gene therapy with the announcement that portfolio company Ray Therapeutics has closed an upsized, oversubscribed $125 million Series B round, following its recent U.S. FDA Regenerative Medicine Advanced Therapy designation for lead program RTx-015 in retinitis pigmentosa. As a founding investor, 4BIO Capital led Ray Therapeutics’ seed round in 2021, joined the Series A in 2023, and has now participated again, underscoring its conviction in the platform and expanding its exposure to late-stage vision-restoration assets.
The new capital, led by Janus Henderson Investors alongside major global institutions, materially de-risks Ray Therapeutics’ near- to mid-term clinical and regulatory roadmap, which in turn enhances the value and visibility of 4BIO Capital’s stake ahead of potential partnering or exit scenarios. 4BIO’s Co-founder and Managing Partner, Dima Kuzmin, who sits on Ray Therapeutics’ board, highlighted the firm’s role in steering the company through complex regulatory pathways and scaling its differentiated optogenetic approach that aims to restore visual function rather than merely slow disease progression. With Ray Therapeutics advancing both RTx-015 for retinitis pigmentosa and a second clinical program, RTx-021, for macular diseases including Stargardt disease and geographic atrophy age-related macular degeneration, 4BIO Capital now holds a central position in a platform with multi-indication potential and growing institutional backing, reinforcing its strategy of concentrated investments in precision therapies addressing high unmet need.